Toripalimab plus cryoablation for lung cancer with limited progression
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type called non-small cell lung cancer that has spread to other parts of the body (stage IV).
- Your cancer must not have certain gene mutations (called driver genes) and must have started growing again in only 1 to 5 spots, in no more than 3 organs, after your first treatment.
- You must be between 18 and 75 years old and in generally good health (able to do daily activities with little help).
- You must be willing to provide blood and tumor tissue samples for testing.
- You cannot have had certain prior treatments like targeted therapy or have active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab), chemotherapy, and a procedure called cryoablation (freezing the tumor) for people with a type of lung cancer called non-small cell lung cancer that has spread or come back. The goal is to see if this combination is safe and effective.
This trial tests a treatment for early-stage lung cancer (stage I-IIA) that uses extreme cold to freeze and destroy the tumor, called cryoablation. Some patients will also receive an immunotherapy drug called serplulimab, which helps the immune system fight the cancer, to see if adding it improves outcomes.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after lung cancer surgery can help stop the cancer from coming back. It is for people with non-small cell lung cancer that has not spread to the brain and does not have certain genetic changes (EGFR/ALK mutations).
This study tests a combination treatment for lung cancer that is blocking the airway. It uses freezing (cryoablation) to shrink the tumor in the airway, along with chemotherapy and an immunotherapy drug (a treatment that helps your immune system fight cancer). The goal is to see if this approach is safe and effective for people who have not had prior treatment.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests a combination of a drug that helps your immune system fight cancer (serplulimab) and a procedure that freezes and destroys cancer cells (cryoablation) for people with early-stage non-small cell lung cancer who cannot or choose not to have surgery or radiation. The goal is to see if this combination is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.